Helena Mora-Jensen

1.2k total citations
17 papers, 929 citations indexed

About

Helena Mora-Jensen is a scholar working on Immunology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Helena Mora-Jensen has authored 17 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 8 papers in Molecular Biology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Helena Mora-Jensen's work include Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (5 papers). Helena Mora-Jensen is often cited by papers focused on Lymphoma Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (5 papers). Helena Mora-Jensen collaborates with scholars based in Denmark, United States and Sweden. Helena Mora-Jensen's co-authors include Adrian Wiestner, Marc A. Weniger, Patricia Pérez‐Galán, Niels Borregaard, Weiping Chen, William C. Trenkle, Tsonwin Hai, David Ron, Yihong Ye and Qiuyan Wang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and The Journal of Immunology.

In The Last Decade

Helena Mora-Jensen

17 papers receiving 923 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Helena Mora-Jensen Denmark 11 453 308 203 188 182 17 929
Lorraine Tracey United States 15 580 1.3× 216 0.7× 154 0.8× 181 1.0× 62 0.3× 20 1.1k
Caroline Bret France 13 455 1.0× 316 1.0× 68 0.3× 102 0.5× 98 0.5× 34 915
Sebastian Herzog Germany 21 713 1.6× 485 1.6× 214 1.1× 122 0.6× 66 0.4× 43 1.4k
Ningshu Liu Germany 11 561 1.2× 340 1.1× 225 1.1× 224 1.2× 72 0.4× 30 1.1k
Charis E. Teh Australia 16 428 0.9× 404 1.3× 234 1.2× 164 0.9× 43 0.2× 34 946
Laurence Cooke United States 19 532 1.2× 215 0.7× 149 0.7× 213 1.1× 195 1.1× 39 1.1k
Bellinda A. Bladergroen Netherlands 17 399 0.9× 471 1.5× 71 0.3× 99 0.5× 75 0.4× 19 1.0k
Valentina A. Schmidt United States 16 588 1.3× 163 0.5× 167 0.8× 35 0.2× 212 1.2× 24 1.1k
Jérôme Paggetti Luxembourg 18 1.2k 2.6× 691 2.2× 178 0.9× 87 0.5× 104 0.6× 38 1.9k
Kirsten Neubert Germany 10 414 0.9× 483 1.6× 102 0.5× 41 0.2× 115 0.6× 13 1.0k

Countries citing papers authored by Helena Mora-Jensen

Since Specialization
Citations

This map shows the geographic impact of Helena Mora-Jensen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helena Mora-Jensen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helena Mora-Jensen more than expected).

Fields of papers citing papers by Helena Mora-Jensen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helena Mora-Jensen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helena Mora-Jensen. The network helps show where Helena Mora-Jensen may publish in the future.

Co-authorship network of co-authors of Helena Mora-Jensen

This figure shows the co-authorship network connecting the top 25 collaborators of Helena Mora-Jensen. A scholar is included among the top collaborators of Helena Mora-Jensen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helena Mora-Jensen. Helena Mora-Jensen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Eriksson, Frank, et al.. (2021). The HLA-DR4-DQ8 phenotype of the recipient is associated with increased mortality after kidney transplantation. Clinical Immunology. 226. 108711–108711. 2 indexed citations
2.
Mora-Jensen, Helena, Jacob Hald, Anne Werner Hauge, Henrik Sengeløv, & Helle Brüünsgaard. (2021). Identification of the novel HLA allele, HLA‐DPA1*01:46, identified in a man of Serbian origin. HLA. 98(1). 79–81. 2 indexed citations
3.
Hald, Jacob, Helena Mora-Jensen, Søren Schwartz Sørensen, Helle Brüünsgaard, & Hans O. Madsen. (2019). Identification of the novel HLA allele, HLA‐C*07:780, identified in a Danish woman. HLA. 95(1). 69–71. 2 indexed citations
4.
Niemann, Carsten Utoft, Helena Mora-Jensen, Eman L. Dadashian, et al.. (2017). Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model. Clinical Cancer Research. 23(19). 5814–5823. 25 indexed citations
5.
Herman, Sarah E. M., Arnau Montraveta, Carsten Utoft Niemann, et al.. (2016). The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23(11). 2831–2841. 121 indexed citations
6.
Mora-Jensen, Helena, Carsten Utoft Niemann, Michael Gulrajani, et al.. (2016). Abstract 4797: The combination of ACP-196 and ACP-319 leads to increased survival in the TCL1-192 CLL mouse model. Cancer Research. 76(14_Supplement). 4797–4797. 1 indexed citations
7.
Borup, Rehannah, Anne Fischer‐Nielsen, Helena Mora-Jensen, et al.. (2016). Changes in Gene Expression during G-CSF–Induced Emergency Granulopoiesis in Humans. The Journal of Immunology. 197(5). 1989–1999. 31 indexed citations
8.
Herman, Sarah E. M., Arnau Montraveta, Carsten Utoft Niemann, et al.. (2015). The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia. Blood. 126(23). 2920–2920. 6 indexed citations
9.
Hu, Nan, Helena Mora-Jensen, Kim Theilgaard‐Mönch, et al.. (2014). Differential Expression of Granulopoiesis Related Genes in Neutrophil Subsets Distinguished by Membrane Expression of CD177. PLoS ONE. 9(6). e99671–e99671. 38 indexed citations
10.
Larsen, Maria Torp, Andreas Glenthøj, Fazila Asmar, et al.. (2014). miRNA-130a regulates C/EBP-ε expression during granulopoiesis. Blood. 123(7). 1079–1089. 34 indexed citations
11.
Rapin, Nicolas, Frederik Otzen Bagger, Johan Jendholm, et al.. (2013). Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. Blood. 123(6). 894–904. 106 indexed citations
12.
Clemmensen, Stine Novrup, Sara Rørvig, Andreas Glenthøj, et al.. (2011). Olfactomedin 4 defines a subset of human neutrophils. Journal of Leukocyte Biology. 91(3). 495–500. 102 indexed citations
13.
Mora-Jensen, Helena, Johan Jendholm, Anna Fossum, et al.. (2011). Technical Advance: Immunophenotypical characterization of human neutrophil differentiation. Journal of Leukocyte Biology. 90(3). 629–634. 33 indexed citations
14.
Pérez‐Galán, Patricia, Helena Mora-Jensen, Marc A. Weniger, et al.. (2010). Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood. 117(2). 542–552. 90 indexed citations
15.
Wang, Qiuyan, Helena Mora-Jensen, Marc A. Weniger, et al.. (2009). ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proceedings of the National Academy of Sciences. 106(7). 2200–2205. 285 indexed citations
16.
17.
Mora-Jensen, Helena, Edgar Gil Rizzatti, & Adrian Wiestner. (2006). Resistance to Bortezomib Develops Slowly in MCL Cells, Extends to the Class of Proteasome Inhibitors, and Is Associated with Decreased Proliferation of the Resistant Cells.. Blood. 108(11). 4397–4397. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lorraine Tracey Breakdown of academic impact, for papers by Caroline Bret Breakdown of academic impact, for papers by Sebastian Herzog Breakdown of academic impact, for papers by Ningshu Liu Breakdown of academic impact, for papers by Charis E. Teh Breakdown of academic impact, for papers by Laurence Cooke Breakdown of academic impact, for papers by Bellinda A. Bladergroen Breakdown of academic impact, for papers by Valentina A. Schmidt Breakdown of academic impact, for papers by Jérôme Paggetti Breakdown of academic impact, for papers by Kirsten Neubert
Rankless by CCL
2026